Kerala Ayurveda Ltd
Incorporated in 1945, Kerala Ayurveda Ltd is engaged In Ayurvedlc services and products[1]
- Market Cap ₹ 376 Cr.
- Current Price ₹ 312
- High / Low ₹ 417 / 234
- Stock P/E
- Book Value ₹ 33.8
- Dividend Yield 0.00 %
- ROCE 4.88 %
- ROE -0.95 %
- Face Value ₹ 10.0
Pros
Cons
- Stock is trading at 9.23 times its book value
- Company has low interest coverage ratio.
- Company has a low return on equity of 2.08% over last 3 years.
- Earnings include an other income of Rs.0.44 Cr.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
22.48 | 25.54 | 28.28 | 32.51 | 39.62 | 43.77 | 46.49 | 53.68 | 43.20 | 55.59 | 63.08 | 72.64 | 68.33 | |
19.87 | 22.68 | 25.02 | 28.49 | 34.82 | 38.10 | 43.48 | 50.58 | 42.99 | 47.86 | 58.15 | 67.58 | 68.20 | |
Operating Profit | 2.61 | 2.86 | 3.26 | 4.02 | 4.80 | 5.67 | 3.01 | 3.10 | 0.21 | 7.73 | 4.93 | 5.06 | 0.13 |
OPM % | 11.61% | 11.20% | 11.53% | 12.37% | 12.12% | 12.95% | 6.47% | 5.77% | 0.49% | 13.91% | 7.82% | 6.97% | 0.19% |
0.20 | 0.21 | 0.04 | 0.14 | 0.14 | 0.26 | 1.53 | 0.16 | 0.17 | 0.30 | 2.89 | 0.16 | 0.44 | |
Interest | 0.77 | 1.01 | 1.14 | 1.14 | 1.14 | 2.02 | 2.23 | 1.37 | 6.14 | 6.03 | 4.81 | 4.02 | 2.72 |
Depreciation | 0.68 | 0.57 | 0.58 | 0.52 | 0.56 | 0.51 | 0.56 | 0.68 | 0.82 | 0.77 | 0.64 | 0.77 | 0.80 |
Profit before tax | 1.36 | 1.49 | 1.58 | 2.50 | 3.24 | 3.40 | 1.75 | 1.21 | -6.58 | 1.23 | 2.37 | 0.43 | -2.95 |
Tax % | 33.09% | 30.87% | 29.75% | 30.80% | 31.79% | 32.35% | 31.43% | 28.10% | -24.77% | 28.46% | -21.94% | 162.79% | |
0.90 | 1.03 | 1.11 | 1.73 | 2.20 | 2.30 | 1.20 | 0.88 | -4.95 | 0.89 | 2.89 | -0.27 | -2.82 | |
EPS in Rs | 0.85 | 0.98 | 1.05 | 1.64 | 2.08 | 2.18 | 1.14 | 0.83 | -4.69 | 0.84 | 2.74 | -0.22 | -2.36 |
Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | 11% |
5 Years: | 9% |
3 Years: | 19% |
TTM: | 7% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 25% |
TTM: | -1063% |
Stock Price CAGR | |
---|---|
10 Years: | 24% |
5 Years: | 47% |
3 Years: | 64% |
1 Year: | 34% |
Return on Equity | |
---|---|
10 Years: | 3% |
5 Years: | -4% |
3 Years: | 2% |
Last Year: | -1% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 10.56 | 10.56 | 10.56 | 10.56 | 10.56 | 10.56 | 10.56 | 10.56 | 10.56 | 10.56 | 10.56 | 12.03 | 12.03 |
Reserves | 1.85 | 2.88 | 3.39 | 5.12 | 4.27 | 7.12 | 2.94 | 4.11 | -0.51 | 0.72 | 3.98 | 30.34 | 28.67 |
57.99 | 60.47 | 64.44 | 64.02 | 51.98 | 69.59 | 56.29 | 57.80 | 66.02 | 61.39 | 63.63 | 61.81 | 55.81 | |
5.47 | 5.29 | 5.27 | 4.77 | 9.44 | 12.73 | 17.37 | 21.13 | 20.16 | 19.03 | 20.53 | 19.87 | 19.59 | |
Total Liabilities | 75.87 | 79.20 | 83.66 | 84.47 | 76.25 | 100.00 | 87.16 | 93.60 | 96.23 | 91.70 | 98.70 | 124.05 | 116.10 |
17.05 | 17.77 | 16.61 | 16.26 | 16.50 | 16.49 | 16.62 | 17.09 | 26.43 | 27.96 | 30.32 | 30.25 | 32.11 | |
CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 6.08 | 8.65 | 9.94 | 11.55 | 2.34 | 2.34 | 0.00 | 0.00 | 0.79 |
Investments | 11.44 | 11.44 | 11.46 | 11.46 | 11.47 | 11.47 | 11.47 | 11.47 | 11.37 | 11.37 | 11.37 | 11.37 | 11.37 |
47.38 | 49.99 | 55.59 | 56.75 | 42.20 | 63.39 | 49.13 | 53.49 | 56.09 | 50.03 | 57.01 | 82.43 | 71.83 | |
Total Assets | 75.87 | 79.20 | 83.66 | 84.47 | 76.25 | 100.00 | 87.16 | 93.60 | 96.23 | 91.70 | 98.70 | 124.05 | 116.10 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
-0.78 | -0.09 | 0.28 | 2.47 | 1.53 | -10.87 | 9.34 | 4.71 | -0.91 | 8.75 | 9.12 | -4.22 | |
-4.45 | -2.01 | -1.55 | -0.65 | -2.50 | -2.20 | -1.70 | -3.93 | -2.10 | 0.83 | -5.32 | -2.18 | |
5.20 | 1.46 | 2.83 | -1.57 | 0.66 | 16.05 | -11.14 | 0.29 | 2.18 | -10.52 | -2.27 | 21.15 | |
Net Cash Flow | -0.03 | -0.64 | 1.55 | 0.25 | -0.30 | 2.98 | -3.50 | 1.06 | -0.83 | -0.94 | 1.52 | 14.75 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 69.49 | 60.60 | 56.27 | 59.06 | 57.30 | 59.79 | 69.25 | 61.67 | 82.55 | 68.02 | 69.84 | 84.37 |
Inventory Days | 259.68 | 299.45 | 283.12 | 234.09 | 368.97 | 380.27 | 326.98 | 307.11 | 237.99 | 212.65 | 200.07 | 243.33 |
Days Payable | 162.40 | 103.46 | 104.07 | 57.56 | 78.16 | 122.56 | 114.67 | 150.61 | 125.76 | 121.74 | 123.60 | 115.18 |
Cash Conversion Cycle | 166.77 | 256.59 | 235.32 | 235.59 | 348.11 | 317.51 | 281.56 | 218.18 | 194.78 | 158.93 | 146.31 | 212.52 |
Working Capital Days | 56.83 | 74.89 | 92.93 | 92.74 | 124.28 | 250.84 | 141.71 | 94.11 | 127.67 | 57.52 | 44.50 | 84.72 |
ROCE % | 3.18% | 3.17% | 3.57% | 4.60% | 5.98% | 7.04% | 3.44% | 3.63% | -0.59% | 9.76% | 5.77% | 4.88% |
Documents
Announcements
- Announcement under Regulation 30 (LODR)-Newspaper Publication 15 Nov
- Financial Results Q2 2024 15 Nov
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
15 Nov - KAL reports 23% revenue growth and plans global expansion.
-
Board Meeting Outcome for Outcome Of Board Meeting
14 Nov - Approved unaudited financial results for Q2 FY2024.
-
Board Meeting Intimation for The Quarter Ended 30Th Sept 2024
11 Nov - Board meeting to approve financial statements for Q2 2024.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Concalls
-
Nov 2018TranscriptNotesPPT
Business Overview:[1]
Company manufactures Ayurveda products and deals in Ayurveda Research, Academies, Clinics, Hospitals, Ayurvedic Wellness Resorts and Services, cultivation of Ayurveda herbs, and maintaining a herbarium of medicinal plants